2 Information about pembrolizumab

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, MSD) is indicated 'for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage 2B, 2C or 3 melanoma and who have undergone complete resection'.

2.2 Pembrolizumab is also recommended for the adjuvant treatment of resected stage 3 melanoma (NICE technology appraisal guidance 766).

Dosage in the marketing authorisation

2.3 The dosage schedule is available in the summary of product characteristics for pembrolizumab.


2.4 The list price is £2,630.00 per 100 mg/4 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed August 2022).

2.5 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.